kidney disease glp 1 GLP-1 agonists in the treatment of chronic in type 2 diabetes and obesity GLP-1 Use in Non-Diabetics Associated

At Laser Lipo and Veins, we offer expert guidance, personalized treatment plans, and ongoing support to help you reach your goals safely and effectively

The STEP 1 trial for semaglutide 2.4mg demonstrated a mean body weight reduction of approximately 14.9% over 68 weeks in adults with obesity. The SURMOUNT-1 trial for tirzepatide showed reductions of up to 22.5% at the highest dose. These are outcomes that approach the efficacy of bariatric surgery in some patient cohorts

Prado CM, Phillips SM, Gonzalez MC, Heymsfield SB

Sin embargo, estos productos no estn aprobados por la Administracin de Alimentos y Medicamentos de Estados Unidos (FDA)

Journal of Endocrinology, 204